Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 7Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Polycystic Ovary Syndrome 1Osteoporosis 1Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Diarrhea 1Cardiovascular Diseases 1Carcinoma, Squamous Cell 1Adenocarcinoma 1

Interventions

Aspirin 4Blood Pressure 3Vitamin E 2Vitamin D 2Nutrition Assessment 2Metformin 2Geritol 2Diet, Mediterranean 2Cholecalciferol 2phosphoribosylformylglycinamidine synthetase 1glycidol 1ficlatuzumab 1beta Carotene 1acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1Vorinostat 1Vascular Stiffness 1Tumor Necrosis Factor Inhibitors 1Therapeutics 1Sugars 1Spironolactone 1Resistance Training 1Raloxifene Hydrochloride 1Pulse Wave Analysis 1Progestins 1Physical Conditioning, Human 1Omeprazole 1Noninvasive Prenatal Testing 1Naproxen 1Methods 1Lysine Acetyltransferase 5 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Cardiovascular Diseases × Raloxifene Hydrochloride × Clear all
NCT00190593 2007-01-26

Raloxifene Use for The Heart

Eli Lilly and Company

Phase 3 Completed
10,000 enrolled
Breast

Breast Neoplasms, Cardiovascular Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡